Top Industry Leaders in the Narcolepsy Market
Latest Narcolepsy Companies Updates:
Avadel's Xyrem® (sodium oxybate) Avadel received FDA approval for its Xyrem® chewable tablets, offering a new formulation of the existing sodium oxybate medication for cataplexy and excessive daytime sleepiness in narcolepsy patients.
Jazz Pharmaceuticals' Sunosi (solriamfetol) Positive results from a Phase 3 trial in June 2023 demonstrated the efficacy and safety of Sunosi in treating excessive daytime sleepiness associated with narcolepsy.
Takeda's TAK-994, an orexin 2 receptor agonist Phase 2 trial results presented in November 2023 showed promising potential for TAK-994 in improving cataplexy symptoms in narcolepsy patients.
List of Narcolepsy Key companies in the market:
- Jazz Pharmaceuticals plc (Republic of Ireland)
- BIOPROJET (Paris)
- Ligand Pharmaceuticals, Inc. (U.S.)
- Shire (Republic of Ireland)
- Arena Pharmaceuticals, Inc. (U.S.)
- Novartis AG (Switzerland)
- Shionogi Inc. (U.S.)
- Graymark Healthcare, Inc. (U.S.)
- Mylan N.V. (U.S.)
